Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.

Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ.

Clin Cancer Res. 1999 Nov;5(11):3608-16.

2.
3.

Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.

Anderson CJ, Jones LA, Bass LA, Sherman EL, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW.

J Nucl Med. 1998 Nov;39(11):1944-51.

4.

In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.

Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ.

Nucl Med Biol. 1999 Apr;26(3):267-73.

PMID:
10363797
5.

64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.

J Nucl Med. 2001 Feb;42(2):213-21.

6.

Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.

Lewis JS, Laforest R, Lewis MR, Anderson CJ.

Cancer Biother Radiopharm. 2000 Dec;15(6):593-604.

PMID:
11190491
7.

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ.

Int J Cancer. 2001 Dec 15;94(6):873-7.

8.

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M.

Q J Nucl Med Mol Imaging. 2007 Dec;51(4):324-33.

9.

Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ.

Clin Cancer Res. 2004 Dec 15;10(24):8674-82.

10.

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP.

Int J Cancer. 2001 Jun 1;92(5):628-33.

12.

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.

Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. Epub 2005 Jul 15.

PMID:
16021448
13.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
14.

In vitro and in vivo evaluation of copper-64-octreotide conjugates.

Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ.

J Nucl Med. 1995 Dec;36(12):2315-25.

15.

Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer.

Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ.

Cancer Res. 2003 Oct 15;63(20):6864-9.

16.
17.

Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats.

Bugaj JE, Erion JL, Johnson MA, Schmidt MA, Srinivasan A.

Nucl Med Biol. 2001 Apr;28(3):327-34.

PMID:
11323245
18.

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP.

J Nucl Med. 2001 Dec;42(12):1841-6.

19.

Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.

Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, de Jong M.

Cancer Biother Radiopharm. 2007 Feb;22(1):151-9.

PMID:
17627424
20.

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP.

J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S.

Supplemental Content

Support Center